Newsroom

April 2015

• Press release Apr 23, 2015

  Novartis delivered sales growth (cc), significant margin expansion (cc) and strong innovation in Q1[1]; now with a more focused portfolio

  Continuing operations[1] saw sales, core[2] operating income and core EPS grow (cc[2]) in Q1 Net sales were USD 11.9 billion (-7%, +3% cc)[2] Operating income was USD 2.8 billion (-1%, +15% cc)…
• Press release Apr 23, 2015

  Novartis a affiché, au T1[1], une forte progression de ses ventes (tcc), une hausse importante de sa marge (tcc) et une innovation très dynamique; avec un portefeuille désormais mieux ciblé

  Ventes, résultat opérationnel core[2] et BPA core (tcc[2]) des activités poursuivies[1] en hausse au T1 Chiffre d'affaires net s'élevant à USD 11,9 milliards (-7%, +3% tcc)]2] Résultat…
• Press release Apr 23, 2015

  Novartis erzielt im ersten Quartal[1] Umsatzsteigerungen (kWk), deutlich höhere Margen (kWk) und beachtliche Innovationen - jetzt mit einem stärker fokussierten Portfolio

  Die fortzuführenden Geschäftsbereiche[1] steigern im ersten Quartal den Umsatz, das operative Kernergebnis[2] und den Kerngewinn pro Aktie (kWk[2]) Der Nettoumsatz beläuft sich auf USD 11,9…
• Press release Apr 21, 2015

  Novartis celebrates 19th annual Community Partnership Day with more than 27,000 associates volunteering in their local communities

  More than 27,000 Novartis associates worldwide dedicate an estimated 200,000 hours to volunteer with charitable causes in their communities  Community Partnership Day symbolizes the company'…
• 
  Story Apr 21, 2015 From Our Labs

  Nurturing the life science ecosystem

• Press release Apr 21, 2015

  Data at AAN showed Gilenya® high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patients

  New FREEDOMS/FREEDOMS II sub-group analysis showed Gilenya-treated patients were six-times more likely to achieve 'no evidence of disease activity  (NEDA4)' vs placebo NEDA4 is based on four…
• 
  Story Apr 17, 2015 Discovery

  How a love of sport led to a scientific breakthrough

  Jeff Weers’ passion inspired a new way of getting inhaled medicine past the body’s natural defenses to reach the lungs.

• Press release Apr 16, 2015

  Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone® 20mg

  Glatopa is the first FDA-approved, substitutable generic version of Copaxone®  20mg, a treatment for relapsing forms of multiple sclerosis Novartis and Sandoz are driving access to a full…
• Press release Apr 16, 2015

  Alcon receives FDA approval of new multifocal intraocular lens to treat cataract patients in the United States

  US Food and Drug Administration (FDA) grants approval of the AcrySof® IQ ReSTOR® +2.5 Diopter (D) Intraocular Lens (IOL) for sale in the US   Expands Alcon's IOL portfolio for the …
• Press release Apr 15, 2015

  Data in The Lancet show Novartis drug Arzerra® plus chlorambucil improved median progression-free survival by 71% in CLL patients

  Significant improvement in PFS seen with Arzerra plus chlorambucil in previously untreated patients with CLL for whom fludarabine-based therapy was inappropriate  Chronic lymphocytic…
• 
  Story Apr 13, 2015 From Our Labs

  Cancer spies find drug-beating covert cells

• Press release Apr 13, 2015

  Gilenya® data at AAN to highlight Novartis leadership in innovation with new MS assessment methods to benefit patients and physicians

  New analysis will confirm high efficacy of Gilenya® in achieving 'no evidence of disease activity' (NEDA4) in previously-treated highly-active RMS patients Separate analyses will show adding…